These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 35697332)

  • 1. Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infection.
    Sulkowski MS; Agarwal K; Ma X; Nguyen TT; Schiff ER; Hann HL; Dieterich DT; Nahass RG; Park JS; Chan S; Han SB; Gane EJ; Bennett M; Alves K; Evanchik M; Yan R; Huang Q; Lopatin U; Colonno R; Ma J; Knox SJ; Stamm LM; Bonacini M; Jacobson IM; Ayoub WS; Weilert F; Ravendhran N; Ramji A; Kwo PY; Elkhashab M; Hassanein T; Bae HS; Lalezari JP; Fung SK; Yuen MF
    J Hepatol; 2022 Nov; 77(5):1265-1275. PubMed ID: 35697332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of vebicorvir in virologically suppressed patients with chronic hepatitis B virus infection.
    Yuen MF; Agarwal K; Ma X; Nguyen TT; Schiff ER; Hann HL; Dieterich DT; Nahass RG; Park JS; Chan S; Han SB; Gane EJ; Bennett M; Alves K; Evanchik M; Yan R; Huang Q; Lopatin U; Colonno R; Ma J; Knox SJ; Stamm LM; Bonacini M; Jacobson IM; Ayoub WS; Weilert F; Ravendhran N; Ramji A; Kwo PY; Elkhashab M; Hassanein T; Bae HS; Lalezari JP; Fung SK; Sulkowski MS
    J Hepatol; 2022 Sep; 77(3):642-652. PubMed ID: 35460726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B.
    Lok AS; Trinh H; Carosi G; Akarca US; Gadano A; Habersetzer F; Sievert W; Wong D; Lovegren M; Cohen D; Llamoso C
    Gastroenterology; 2012 Sep; 143(3):619-628.e1. PubMed ID: 22643350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiviral efficacy of entecavir in nucleos(t)ide-naïve patients of Black/African descent with chronic hepatitis B.
    Jeffers L; Van Rensburg CJ; Banks A; Schechter M; Schmidt SJ; Hu W; Llamoso C; Parana R
    J Viral Hepat; 2014 Jan; 21(1):74-6. PubMed ID: 24112755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial.
    Yuen MF; Agarwal K; Gane EJ; Schwabe C; Ahn SH; Kim DJ; Lim YS; Cheng W; Sievert W; Visvanathan K; Ruby E; Liaw S; Yan R; Huang Q; Colonno R; Lopatin U
    Lancet Gastroenterol Hepatol; 2020 Feb; 5(2):152-166. PubMed ID: 31711752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Covalently closed-circular hepatitis B virus DNA reduction with entecavir or lamivudine.
    Bowden S; Locarnini S; Chang TT; Chao YC; Han KH; Gish RG; de Man RA; Yu M; Llamoso C; Tang H
    World J Gastroenterol; 2015 Apr; 21(15):4644-51. PubMed ID: 25914474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 240-week entecavir maleate treatment in Chinese chronic hepatitis B predominantly genotype B or C.
    Xu JH; Fan YN; Yu YY; Si CW; Zeng Z; Xu ZN; Li J; Mao Q; Zhang DZ; Tang H; Sheng JF; Chen XY; Ning Q; Shi GF; Xie Q; Zhang XQ; Dai J
    J Viral Hepat; 2022 Oct; 29(10):862-867. PubMed ID: 35737855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of entecavir versus lamivudine over 5 years of treatment: A randomized controlled trial in Korean patients with hepatitis B e antigen-negative chronic hepatitis B.
    Lee KS; Kweon YO; Um SH; Kim BH; Lim YS; Paik SW; Heo J; Lee HJ; Kim DJ; Kim TH; Lee YS; Byun KS; Kim D; Lee MS; Yu K; Suh DJ
    Clin Mol Hepatol; 2017 Dec; 23(4):331-339. PubMed ID: 28946736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of entecavir treatment for up to 5 years in nucleos(t)ide-naïve chronic hepatitis B patients in real life.
    Luo J; Li X; Wu Y; Lin G; Pang Y; Zhang X; Ao Y; Du Z; Zhao Z; Chong Y
    Int J Med Sci; 2013; 10(4):427-33. PubMed ID: 23471472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monotherapy with tenofovir disoproxil fumarate for adefovir-resistant vs. entecavir-resistant chronic hepatitis B: A 5-year clinical trial.
    Lim YS; Gwak GY; Choi J; Lee YS; Byun KS; Kim YJ; Yoo BC; Kwon SY; Lee HC
    J Hepatol; 2019 Jul; 71(1):35-44. PubMed ID: 30876946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Analysis of a randomized, double-blind, double-dummy, controlled, multicenter study confirmed the similar therapeutic efficacies of entecavir maleate and entecavir for treatment of HBeAg-positive chronic hepatitis B].
    Xu JH; Yu YY; Si CW; Zeng Z; Li J; Mao Q; Zhang DZ; Tang H; Sheng JF; Chen XY; Ning Q; Shi GF; Xie Q; Zhang XQ; Dai J; Xu ZN
    Zhonghua Gan Zang Bing Za Zhi; 2013 Dec; 21(12):881-5. PubMed ID: 24636286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of prolonged entecavir monotherapy in treatment-naïve chronic hepatitis B patients exhibiting a partial virologic response to entecavir.
    Choi HN; Song JE; Lee HC; Jo HH; Lee CH; Kim BS
    Clin Mol Hepatol; 2015 Mar; 21(1):24-31. PubMed ID: 25834799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of 2years of entecavir plus adefovir therapy in patients with chronic hepatitis B who had failed on prior nucleos(t)ide analog treatment.
    Wang X; Zhang C; Zhu Y; Xiong Y; Wang Y
    Antiviral Res; 2014 Mar; 103():71-7. PubMed ID: 24462954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emergence of entecavir-resistant mutations in nucleos(t)ide-naive Japanese patients infected with hepatitis B virus: virological breakthrough is also dependent on adherence to medication.
    Kamezaki H; Kanda T; Wu S; Nakamoto S; Arai M; Maruyama H; Fujiwara K; Imazeki F; Yokosuka O
    Scand J Gastroenterol; 2011 Sep; 46(9):1111-7. PubMed ID: 21623676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir.
    Leung N; Peng CY; Hann HW; Sollano J; Lao-Tan J; Hsu CW; Lesmana L; Yuen MF; Jeffers L; Sherman M; Min A; Mencarini K; Diva U; Cross A; Wilber R; Lopez-Talavera J
    Hepatology; 2009 Jan; 49(1):72-9. PubMed ID: 19065670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy.
    Li N; Xu JH; Yu M; Wang S; Si CW; Yu YY
    World J Gastroenterol; 2015 Nov; 21(43):12421-9. PubMed ID: 26604649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Entecavir plus tenofovir combination therapy for chronic hepatitis B in patients with previous nucleos(t)ide treatment failure.
    Zoulim F; Białkowska-Warzecha J; Diculescu MM; Goldis AE; Heyne R; Mach T; Marcellin P; Petersen J; Simon K; Bendahmane S; Klauck I; Wasiak W; Janssen HL
    Hepatol Int; 2016 Sep; 10(5):779-88. PubMed ID: 27206517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trial.
    Lim YS; Byun KS; Yoo BC; Kwon SY; Kim YJ; An J; Lee HC; Lee YS
    Gut; 2016 May; 65(5):852-60. PubMed ID: 25596179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term virological outcome in chronic hepatitis B patients with a partial virological response to entecavir.
    Jo YJ; Kim KA; Lee JS; Kim NH; Bae WK; Song TJ; Kim JW
    Korean J Intern Med; 2015 Mar; 30(2):170-6. PubMed ID: 25750558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiviral efficacy of entecavir versus entecavir plus adefovir for hepatitis B virus rtA181V/T mutants alone.
    Oh MJ; Lee HJ
    Saudi J Gastroenterol; 2016; 22(1):37-42. PubMed ID: 26831605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.